Market Overview

Bernstein Weighs In On Vertex Move

Related VRTX
Should You Buy Vertex Pharmaceuticals (VRTX) Ahead of Earnings? - Tale of the Tape
Vertex Is Poised For An Earnings Breakout

As shares of Vertex Pharmaceuticals (NASDAQ: VRTX) have rallied over 40 percent following a press release concerning phase 3 studies of its Lumacaftor Ivacaftor combination regime, Bernstein analyst Geoffrey Porges issued a note with his take on the stock

Despite Tuesday's move, Porges maintained his Market Perform rating and $65 price target.

Porges noted the data are "clearly better than expected," but believes the immediate potential of the combination is substantially priced in. Moreover, he thinks short-covering will initially exaggerate the move.

Looking forward, Porges expects the regimen to receive FDA approval.

For a more detailed look into the press release, click here.

Posted-In: Bernstein Geoffrey PorgesAnalyst Color News Price Target Reiteration Analyst Ratings

 

Most Popular

Related Articles (VRTX)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters